New Research Shows Promise in Regional Delivery of CAR-T Therapy
DENVER--(BUSINESS WIRE)--Jul 13, 2018--Surefire Medical, Inc. (Surefire), an oncology drug delivery company, announced the publication of “Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy” in the ISSUE of the Journal of Interventional Radiology.
The study suggests that further development of chimeric antigen receptor T cells (CAR-T) therapy should be done in combination with novel devices to allow for regional delivery of therapy into solid tumors.
The evolution of immuno-oncology therapies and the use of CAR-T have shown significant benefits in the systemic treatment of blood cancers, such as acute lymphoblastic leukemia (ALL). Despite these advances, challenges remain in the safety and effectiveness for CAR-T in solid tumors.
A variety of approaches are being explored comparing regional versus systemic delivery of CAR-T, one of which is the use of microvalve infusion (MVI) catheters to deliver therapy into solid tumors. MVI systems have shown in both clinical and preclinical studies to increase the depth and concentration of delivery of non-cellular therapies into tumors and less to non-target tissue. In one ongoing study, the Surefire Infusion System (SIS) is under evaluation in the treatment of liver metastases and the ability to overcome interstitial fluid pressure.
Elevated interstitial fluid pressure is one component of a dynamic microenvironment found in solid tumors. Other challenges include aberrant vasculature and the migration of dense stroma. All of these dynamics make direct delivery to the tumor site difficult and can either limit dosing or lead to off-tumor toxicities from residual drug leaving the tumor site.
“We’re really beginning to understand the unique and challenging nature of solid tumors. With this knowledge, we’re looking for ways to overcome barriers posed by tumors and combine novel devices with CAR-T therapy. We hope this combination will result in better outcomes for patients,” said Mary Szela, CEO and President of Surefire.
About Pressure-enabled Drug Delivery™ (PEDD)
The high intratumoral pressure created by the tumor microenvironment limits the flow and accumulation of therapy in solid tumors. Microvalve infusion catheters (MVI) employing Pressure-enabled Drug Delivery™ (PEDD) can improve drug delivery to the tumor by creating a favorable pressure gradient that penetrates the hostile tumor microenvironment and increases drug concentration in the tumor without increasing systemic toxicity. Locoregional infusion with the Surefire-patented technology has been used in approximately 8,000 procedures worldwide for liver cancer and can be applied to a variety of other high-pressure solid tumors.
About Surefire Medical
Surefire Medical is a privately held medical device firm in Westminster, CO, focused on making the administration of cancer therapies safer and more effective for patients. Surefire Medical created the Pressure-enabled Drug Delivery™ (PEDD) technology and is committed to developing other applications of the technology for use in other solid tumors and for the administration of immuno-oncology (IO) therapies. Surefire Medical was founded in 2011. For more information, visit surefiremedical.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180713005038/en/
CONTACT: Surefire Medical, Inc.
Rachel Garcia, + 1-888-321-5212
KEYWORD: UNITED STATES NORTH AMERICA COLORADO
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY
SOURCE: Surefire Medical, Inc.
Copyright Business Wire 2018.
PUB: 07/13/2018 09:02 AM/DISC: 07/13/2018 09:02 AM